Recruiting
Phase 2

KT-621

Sponsor:

Kymera Therapeutics, Inc.

Code:

NCT07677059

Conditions

Asthma (Diagnosis)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

KT-621

Study Details

Brief summary:

This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.

Conditions

Asthma (Diagnosis)

Study ID

NCT07677059

Start date

Jun 25, 2026

Status verified date

Jun, 2026

Completion date

Dec, 2028

Anticipated

Primary completion date

Dec, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Must have completed all visits of the parent study, per its protocol, up to the end of treatment (EoT) visit.
  • Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.
  • Must agree to contraceptive requirements in compliance with the clinical study and local requirements.

Exclusion Criteria:

  • Must not have experienced any clinically significant change in health status during the parent study, which, in the opinion of the Investigator, would interfere with participant safety, study evaluations, or compliance with study procedures; or otherwise make the participant unsuitable for participation in this study.
  • Must not have developed an AE during the parent study, that in the opinion of the Investigator or of the Sponsor's Medical Monitor, could indicate that continued treatment may present an unreasonable risk for the participant.
  • Must not have met permanent discontinuation criteria and/or permanently discontinued study treatment for any reason during the parent study.
  • Must not be a member of the Sponsor or site's investigational team or their immediate family.
  • Must not be unsuitable to enter the study for any other reason, as judged by the Investigator, including potential risk of noncompliance to study procedures.

Study Design

Enrollment

264 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: KT-621

Interventions

KT-621

Oral drug

Primary outcome measure

  • Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: From baseline through Week 52 ]
  • Incidence of treatment-emergent serious adverse events (SAEs) [ Time Frame: From baseline through Week 52 ]

Central Contacts and Locations

Central contacts

Kymera Medical Director

857-285-5300clinicaltrials@kymeratx.com

Locations

Kymera Investigative Site

Recruiting

Miami, Florida, United States, 33173

Kymera Investigative Site

Recruiting

Tampa, Florida, United States, 33607

Kymera Investigative Site

Recruiting

Dallas, Texas, United States, 75209

More Information

Sponsor

Kymera Therapeutics, Inc.

Last update posted

Oct 7, 2026

Last verified

Jun, 2026

Keywords

  • KT-621
  • STAT6
  • stat6 degrader
  • targeted protein degrader
  • Phase 2
  • phase 2b
  • OLE
  • LTE

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-24. This information was provided to ClinicalTrials.gov by Kymera Therapeutics, Inc. on 2026-10-07. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.